Risk of angioedema and thrombolytic therapy among stroke patients: An analysis of data from the FDA Adverse Event Reporting System database

Risk of angioedema and thrombolytic therapy among stroke patients: An analysis of data from the FDA Adverse Event Reporting System database

The angioedema risk may vary among stroke patients receiving different thrombolytic agents. This study aimed to investigate the angioedema risk associated with different thrombolytic agents and to identify associated risk factors. We conducted a large-scale retrospective pharmacovigilance study usin...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hunong Xiang, Yu Ma, Xiaochao Luo, Jian Guo, Minghong Yao, Yanmei Liu, Ke Deng, Xin Sun, Ling Li
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Series:	Neurotherapeutics
Subjects:	Alteplase Tenecteplase Angioedema FAERS
Online Access:	http://www.sciencedirect.com/science/article/pii/S1878747924001612
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system
by: Wei Mao, et al.
Published: (2025-01-01)

Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
by: Qun Li, et al.
Published: (2025-02-01)

Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
by: Ximu Sun, et al.
Published: (2025-02-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
by: Wenchao Lu, et al.
Published: (2025-01-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
by: Ke He, et al.
Published: (2025-01-01)

Personalized biological treatment with lanadelumab in a patient with recurrent attacks of hereditary angioedema
by: Artur Gęsicki, et al.
Published: (2024-08-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01)

Investigation of the correlation of C1 esterase inhibitor levels and functions with attack severity and frequency in hereditary angioedema
by: Fatma Arzu Akkuş, et al.
Published: (2024-06-01)

El Angioedema hereditario en la Provincia de Villa Clara desde 1999 a la actualidad, avances y desafíos
by: Lay Salazar Torres
Published: (2024-05-01)

The latest therapeutic reports on short-term and long-term prophylaxis in the treatment of hereditary angioedema
by: Maciej Kozłowski, et al.
Published: (2024-02-01)

Vasculopathy: a possible factor affecting hereditary angioedema
by: Anna Laura Colia, et al.
Published: (2025-02-01)

Abdominal attack in a patient with hereditary angioedema due to C1 inhibitor deficiency complicated by a perforated peptic ulcer
by: Piotr Obtulowicz, et al.
Published: (2024-02-01)

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-01-01)

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-02-01)

Efficacy of Intravenous Tenecteplase Bridge Thrombectomy for Recurrent Ischemic Stroke Within 3 Months: A Case Report
by: Liu C, et al.
Published: (2025-02-01)

Hereditary angioedema diagnosis evaluation score (HADES): A new clinical scoring system for predicting hereditary angioedema with C1 inhibitor deficiency
by: Ricardo Zwiener, MD, et al.
Published: (2025-05-01)

Awareness of hereditary angioedema among emergency physicians: a survey study
by: Recep Evcen, et al.
Published: (2024-02-01)

Expanding on Abraxane Safety: Temporal Insights and Future Directions for Adverse Event Analysis [Letter]
by: Yang F, et al.
Published: (2025-02-01)

Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system
by: Yixuan Yang, et al.
Published: (2025-01-01)

Disease control and quality of life in chronic spontaneous urticaria and recurrent angioedema are strongly linked, but not in all patients
by: Sophia Neisinger, et al.
Published: (2025-01-01)

A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases
by: Siyu Lou, et al.
Published: (2025-01-01)

N-terminal pro-B-type natriuretic peptide as a predictive marker of the outcomes of fibrinolytic therapy in acute ST-elevation myocardial infarction
by: Amit Kumar, et al.
Published: (2024-04-01)

Perioperative Management of a Patient with Hereditary Angioedema and Intestinal Obstruction Secondary to an Ileal Tumor: A Case Report
by: Antony Peter Gatheru, et al.
Published: (2025-01-01)

Adverse events in the nervous system associated with blinatumomab: a real-world study
by: Wen Gao, et al.
Published: (2025-02-01)

Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
by: Chuang Yang, et al.
Published: (2025-02-01)

Analysis of ADR reports of cetuximab based on the FDA adverse event reporting system database
by: Shuai Zhao, et al.
Published: (2025-02-01)

Indirect treatment comparison of lanadelumab and a C1-esterase inhibitor in pediatric patients with hereditary angioedema
by: Maureen Watt, et al.
Published: (2025-01-01)

De Novo or inherited: gonosomal mosaicism in hereditary angioedema due to C1 inhibitor deficiency
by: Laura Batlle-Masó, et al.
Published: (2025-02-01)

Uncovering a novel SERPING1 pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema
by: Lingxi Jiang, et al.
Published: (2024-09-01)

A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database
by: Yalan Tian, et al.
Published: (2025-01-01)

Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database
by: Bu-kun Zhu, et al.
Published: (2025-02-01)

Drug-induced dementia: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Lisi Xu, et al.
Published: (2025-01-01)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Lingqing Ding, et al.
Published: (2022-01-01)

替奈普酶治疗急性缺血性卒中的研究进展及展望 Research Progress and Prospect of Tenecteplase in the Treatment of Acute Ischemic Stroke
by: 徐露，董漪，董强 (XU Lu, DONG Yi, DONG Qiang)
Published: (2025-01-01)

Data mining and safety analysis of voriconazole in patients with a hematological malignant tumor based on the FAERS database: differences between children and adults
by: Hao Li, et al.
Published: (2025-01-01)

Precision Adverse Drug Reactions Prediction with Heterogeneous Graph Neural Network
by: Yang Gao, et al.
Published: (2025-01-01)

Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system
by: Jingrong Yang, et al.
Published: (2025-01-01)